Arcus biosciences announces two randomized clinical studies to advance ab928, a dual adenosine receptor antagonist, into novel combinations for colorectal and pancreatic cancers

Arcus biosciences, in collaboration with genentech, announces two randomized clinical studies to advance ab928, a dual adenosine receptor antagonist, into novel combinations for colorectal and pancreatic cancers.arcus biosciences inc - additional financial terms of collaboration with genentech were not disclosed.arcus biosciences inc - under agreement, co, genentech is supplying its respective anti-cancer agent to support trial and jointly funding studies.
RCUS Ratings Summary
RCUS Quant Ranking